Profile: BioTime Inc (BTX)
20 Jun 2019
BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company's clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery.
The Company's lead facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus (HIV). OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial (RPE) cells that are derived from pluripotent stem cells. RPE cells form the back lining of the retina, and support the function of photoreceptors (rods and cones). RPE cells can be damaged and lost in various forms of retinal degeneration. In addition to Renevia, the Company has two additional primary programs utilizing its HyStem technology. HyStem- brain-derived neurotrophic factor (BDNF) is a preclinical development program for the delivery of recombinant human BDNF directly into the stroke cavity of patients with the goal of aiding in tissue repair and functional recovery. ReGlyde is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis (OA).
The Company's subsidiary Asterias Biotherapeutics, Inc. (Asterias) is focused on advancing three clinical-stage programs, which have the potential to address areas of unmet medical need in the fields of neurology and oncology. Asterias' lead products are AST-OPC1, AST-VAC1 and AST-VAC2. The Company's affiliate OncoCyte Corporation (OncoCyte) is developing confirmatory diagnostic tests for lung cancer, breast cancer, and bladder cancer utilizing novel liquid biopsy technology. The Company is also developing technology related to an area of regenerative medicine relevant to diseases of aging.
Renevia is being developed to address an immediate need in facial aesthetic procedures, and certain reconstructive surgeries, by improving the process of transplanting a patient's own fat progenitor cells to provide a natural feeling and longer lasting benefit. OpRegen is in a Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration (AMD). AST-OPC1 consists of oligodendrocyte progenitor cells, which are cells that become oligodendrocytes after injection. AST-VAC1 is an Asterias' autologous (patient-specific) cancer vaccine designed to stimulate a patient's immune system to attack telomerase. Asterias is developing AST-VAC1 for the treatment of Acute Myeloid Leukemia (AML), the common form of acute leukemia in adults. AST-VAC2 is developed by Asterias as an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase. AST-VAC2 is produced from human embryonic stem (hES) cells that can be modified with any antigen. The Company, through LifeMap Sciences, Inc., offers biomedical knowledgebases, and Next Generation Sequencing (NGS) data analysis and interpretation solutions. Its subsidiary Cell Cure Neurosciences Ltd. is engaged in providing products to treat age-related macular degeneration. The Company's subsidiary ES Cell International Pte. Ltd. offers stem cell products for research, including clinical grade cell lines.
The Company competes with Astellas Pharma Inc., Integrated Diagnostics, OncImmune Ltd., Exact Sciences Corp, Gensignia Life Sciences, Inc., Veracyte, Inc., Hospira, Teva Pharmaceutical Industries, Ltd., Sanofi-Aventis, Baxter International, Alpha Therapeutics, B. Braun and CJ Health.
1010 Atlantic Ave Ste 102
ALAMEDA CA 94501-1147